Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Metrics to compare | 2QK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2QKPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −1.7x | −0.5x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | 0.0x | 0.9x | 2.6x | |
Price / LTM Sales | 0.0x | 75.6x | 3.2x | |
Upside (Analyst Target) | 0.0% | 311.1% | 41.2% | |
Fair Value Upside | Unlock | 14.5% | 6.2% | Unlock |